share_log

Johnson & Johnson | 8-K: Johnson & Johnson Reports Q1 2024 Results and Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

Johnson & Johnson | 8-K: Johnson & Johnson Reports Q1 2024 Results and Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

強生 | 8-K：強生公布2024年第一季度業績並宣布連續62年增加股息；將季度股息提高4.2%
美股sec公告 ·  04/16 19:10
牛牛AI助理已提取核心訊息
On April 16, 2024, Johnson & Johnson reported its financial results for the first quarter ended March 31, 2024. The company announced a reported sales growth of 2.3% reaching $21.4 billion, with an operational growth of 3.9% and an adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, the adjusted operational growth was 7.7%. Earnings per share (EPS) increased to $2.20, and adjusted EPS rose to $2.71, marking a 12.4% increase. Additionally, Johnson & Johnson's Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, continuing a 62-year streak of consecutive dividend increases. The next dividend is scheduled to be paid on June 4, 2024, to shareholders of record as of May 21, 2024. The company also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The report highlighted the performance of key products and segments, including Innovative Medicine and MedTech, and noted several regulatory approvals and product launches. Johnson & Johnson emphasized its commitment to healthcare innovation and its position in the industry.
On April 16, 2024, Johnson & Johnson reported its financial results for the first quarter ended March 31, 2024. The company announced a reported sales growth of 2.3% reaching $21.4 billion, with an operational growth of 3.9% and an adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, the adjusted operational growth was 7.7%. Earnings per share (EPS) increased to $2.20, and adjusted EPS rose to $2.71, marking a 12.4% increase. Additionally, Johnson & Johnson's Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, continuing a 62-year streak of consecutive dividend increases. The next dividend is scheduled to be paid on June 4, 2024, to shareholders of record as of May 21, 2024. The company also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The report highlighted the performance of key products and segments, including Innovative Medicine and MedTech, and noted several regulatory approvals and product launches. Johnson & Johnson emphasized its commitment to healthcare innovation and its position in the industry.
2024年4月16日，強生公司公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈，銷售額增長2.3％，達到214億美元，運營增長3.9％，調整後的運營增長4.0％。不包括 COVID-19 疫苗，調整後的業務增長爲7.7％。每股收益（EPS）增至2.20美元，調整後的每股收益升至2.71美元，增長12.4％。此外，強生董事會宣佈將季度股息率提高4.2％，從每股1.19美元提高至1.24美元，延續了62年來股息連續增長的勢頭。下一次股息計劃於2024年6月4日支付給截至2024年5月21日的登記股東。該公司還提高了2024年全年營業銷售額並調整了運營每股收益預期。該報告重點介紹了包括創新醫學和醫療技術在內的關鍵產品和細分市場的表現，並指出了幾項監管批准和產品發佈。強生公司強調了其對醫療創新的承諾及其在行業中的地位。
2024年4月16日，強生公司公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈，銷售額增長2.3％，達到214億美元，運營增長3.9％，調整後的運營增長4.0％。不包括 COVID-19 疫苗，調整後的業務增長爲7.7％。每股收益（EPS）增至2.20美元，調整後的每股收益升至2.71美元，增長12.4％。此外，強生董事會宣佈將季度股息率提高4.2％，從每股1.19美元提高至1.24美元，延續了62年來股息連續增長的勢頭。下一次股息計劃於2024年6月4日支付給截至2024年5月21日的登記股東。該公司還提高了2024年全年營業銷售額並調整了運營每股收益預期。該報告重點介紹了包括創新醫學和醫療技術在內的關鍵產品和細分市場的表現，並指出了幾項監管批准和產品發佈。強生公司強調了其對醫療創新的承諾及其在行業中的地位。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。